Table 2.
Multivariable logistic regression model for chemotherapy receipt.
| Variables | Traditional RS cutoffs |
TAILORx RS cutoffs |
||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P | OR | 95%CI | P | |
| Age (continuous variable) (years) | 0.972 | 0.947–0.997 | 0.030 | 0.972 | 0.948–0.996 | 0.023 |
| Race/ethnicity | ||||||
| Non-Hispanic White | 1 | 1 | ||||
| Non-Hispanic Black | 0.797 | 0.583–1.088 | 0.153 | 0.857 | 0.632–1.163 | 0.323 |
| Hispanic (All Races) | 0.856 | 0.647–1.133 | 0.278 | 0.859 | 0.659–1.119 | 0.259 |
| Other | 1.049 | 0.807–1.361 | 0.719 | 1.106 | 0.860–1.423 | 0.432 |
| Grade | ||||||
| Well differentiated | 1 | 1 | ||||
| Moderately differentiated | 1.816 | 1.424–2.316 | <0.001 | 1.821 | 1.443–2.297 | <0.001 |
| Poorly/undifferentiated | 2.885 | 2.152–3.868 | <0.001 | 2.942 | 2.211–3.915 | <0.001 |
| Unknown | 1.456 | 0.749–2.831 | 0.268 | 1.392 | 0.741–2.616 | 0.304 |
| Histology | ||||||
| IDC or mixed with other types of carcinoma | 1 | 1 | ||||
| ILC or mixed with other types of carcinoma | 1.091 | 0.685–1.736 | 0.714 | 1.054 | 0.681–1.631 | 0.814 |
| Other | 0.725 | 0.491–1.070 | 0.105 | 0.758 | 0.523–1.099 | 0.144 |
| Tumor stage | ||||||
| T1 | 1 | 1 | ||||
| T2 | 1.458 | 1.179–1.803 | 0.001 | 1.471 | 1.202–1.801 | <0.001 |
| PR status | 0 | |||||
| Negative | 1 | 1 | ||||
| Positive | 0.984 | 0.657–1.474 | 0.938 | 0.87 | 0.584–1.297 | 0.495 |
| Unknown | 2.827 | 0.535–14.950 | 0.221 | 2.065 | 0.468–9.124 | 0.339 |
| Surgical procedure | ||||||
| BCS | 1 | 1 | ||||
| Mastectomy | 1.718 | 1.287–2.292 | <0.001 | 1.683 | 1.269–2.232 | <0.001 |
| Radiotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 2.022 | 1.508–2.713 | <0.001 | 1.803 | 1.354–2.400 | <0.001 |
| 21-gene recurrence score | ||||||
| Low-risk | 1 | 1 | ||||
| Intermediate-risk | 6.802 | 5.570–8.306 | <0.001 | 5.995 | 3.933–9.138 | <0.001 |
| High-risk | 18.93 | 13.391–26.759 | <0.001 | 31.231 | 19.650–49.637 | <0.001 |
Abbreviations: BCS, breast conserving surgery; CI, confidence interval; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; OR, odds ratio; PR, progesterone receptor; RS, recurrence score; T, tumor; TAILORx, Trial Assigning Individualized Options for Treatment.